Akebia Therapeutics, Inc. (AKBA) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with a 15% revenue increase and a 10% improvement in net loss, indicating operational efficiency. The positive cash position due to a successful equity raise and strategic initiatives in product development further enhance the outlook. Despite the risks associated with forward-looking statements, the overall sentiment is positive, suggesting a potential stock price increase in the short term.
Key Financial Performance
Revenue $60.5 million, a 15% increase year-over-year, driven by strong sales of Vafseo in the U.S. market.
Net Loss $25.3 million, a 10% improvement year-over-year, attributed to cost-cutting measures and operational efficiencies.
Research and Development Expenses $18.7 million, a 5% decrease year-over-year, due to the completion of certain clinical trials.
Cash and Cash Equivalents $120 million, a 20% increase year-over-year, primarily from a successful equity raise during the fiscal year.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The call includes forward-looking statements that are subject to risks and uncertainties, which could cause actual results to differ materially from expectations.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Initiatives: Dr. Steven Burke, our Chief Medical Officer and Head of Research and Development, is available for Q&A dialing in from the Annual Dialysis Conference in Kansas City today, where Akebia will present data on Vafseo this weekend.
Forward-looking Statements: I'd like to remind everyone that this call includes forward-looking statements. Each forward-looking statement on this call is subject to risks and uncertainties that could cause actual results to differ materially from
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Akebia Financial
BTIG LLC
Burke Senior
Butler CEO
CEO President
CFO Treasurer
Carrasco Senior
Chief Research
Communications Butler
Conference Instructions
Corporate Communications
Development Officer
Director IR
Director Senior
Division EST
EST day
Erik Ostrowski
Harrison BTIG
IR statement
Investor Corporate
Julian Harrison
LLC Research
Mercedes Carrasco
Officer Erik
Officer Julian
Officer Senior
President Director
Research Development
Results Conference
Senior VP
Treasurer Burke
VP Chief
day Akebia
today Mercedes
AKBA Transcript
Akebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call reveals a strong financial performance with a 15% YoY revenue increase and reduced net loss, indicating improved operational efficiency. Decreased R&D and operating expenses further enhance financial health. Despite the absence of strategic initiatives and forward-looking statements, the financial metrics suggest a positive market reaction. The lack of Q&A insights limits adjustment, but the financial performance alone supports a positive sentiment.
Akebia Therapeutics, Inc. (AKBA) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-9
Akebia Therapeutics, Inc. (AKBA) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call highlights strong financial performance with a 15% revenue increase and a 10% improvement in net loss, indicating operational efficiency. The positive cash position due to a successful equity raise and strategic initiatives in product development further enhance the outlook. Despite the risks associated with forward-looking statements, the overall sentiment is positive, suggesting a potential stock price increase in the short term.
Akebia Therapeutics, Inc. (AKBA) Q3 2025 Earnings Call Transcript
Positive11-10
The earnings call highlights significant patient access expansion for Vafseo, improved financial performance, and positive physician feedback on clinical data. Although there are operational challenges, strategies are in place to address them. The Q&A reveals enthusiasm for the product and progress in partnerships, despite some uncertainties. Overall, the company's optimistic revenue growth expectations, patient access expansion, and improved net income suggest a positive stock price movement over the next two weeks.
AKBA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
